SCHEMBL22119050

SCHEMBL22119050

OC[C@H]1CO[C@@H](CI)CO1

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22119755 1.00 ALDH1A1 (0.33) ALDH1A1TDP1
SCHEMBL942150 0.86 ALDH1A1 (0.42) ALDH1A1TDP1
SCHEMBL15579093 0.86 ALDH1A1 (0.42) ALDH1A1TDP1
SCHEMBL3746774 0.86 ALDH1A1 (0.42) ALDH1A1TDP1
SCHEMBL3746769 0.86 ALDH1A1 (0.42) ALDH1A1TDP1
SCHEMBL242398 0.86 ALDH1A1 (0.42) ALDH1A1TDP1
SCHEMBL15579092 0.86 ALDH1A1 (0.42) ALDH1A1TDP1
Glycidol SCHEMBL377563 0.83
SCHEMBL588229 0.83
Glycidol SCHEMBL8375576 0.83 ALDH1A1 (0.44) ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12534470-B2 DNA polymerase IIIC inhibitors and use thereof Acurx Pharmaceuticals, Inc. (US) 2026-01-27 US disclosed
US-20230250102-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2023-08-10 US disclosed
US-20220112195-A1 DNA Polymerase IIIC Inhibitors and Use Thereof ACURX PHARMACEUTICALS LLC (US) 2022-04-14 US disclosed
EP-3897645-A1 DNA POLYMERASE IIIC INHIBITORS AND USE THEREOF Acurx Pharmaceuticals, LLC (US) 2021-10-27 EP disclosed
US-11001592-B2 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2021-05-11 US disclosed
US-10836772-B2 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2020-11-17 US disclosed
US-20200308179-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2020-10-01 US disclosed
US-20200308180-A1 DNA Polymerase IIIC Inhibitors and Use Thereof Acurx Pharmaceuticals, Inc. 2020-10-01 US disclosed
US-10723741-B1 DNA polymerase IIIC inhibitors and use thereof ACURX PHARMACEUTICALS, LLC (US) 2020-07-28 US disclosed
WO-2020132174-A1 DNA POLYMERASE IIIC INHIBITORS AND USE THEREOF ACURX PHARMACEUTICALS, LLC (US) 2020-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220112195-A1 DNA Polymerase IIIC Inhibitors and Use Thereof POLI, POLN, POLB ALDH1A1 3028/4885TDP1 90/4885
US-12534470-B2 DNA polymerase IIIC inhibitors and use thereof POLR1A, POLR2H, POLN ALDH1A1 2357/4885TDP1 211/4885
US-20200308180-A1 DNA Polymerase IIIC Inhibitors and Use Thereof POLI, POLN, POLB ALDH1A1 3055/4885TDP1 88/4885
US-20230250102-A1 DNA Polymerase IIIC Inhibitors and Use Thereof POLI, POLN, POLB ALDH1A1 3028/4885TDP1 90/4885
US-20200308179-A1 DNA Polymerase IIIC Inhibitors and Use Thereof POLI, POLN, POLB ALDH1A1 3055/4885TDP1 88/4885
US-11001592-B2 DNA polymerase IIIC inhibitors and use thereof POLI, POLN, POLB ALDH1A1 3055/4885TDP1 88/4885
US-10723741-B1 DNA polymerase IIIC inhibitors and use thereof POLI, POLN, POLB ALDH1A1 3028/4885TDP1 90/4885
US-10836772-B2 DNA polymerase IIIC inhibitors and use thereof POLI, POLN, POLB ALDH1A1 3055/4885TDP1 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.